tickdelta
Sign in
Screener / SEC EDGAR /CIK 0001090872 /10-K filed Dec 22, 2025, compared with Dec 20, 2024 /Numbers from the XBRL of the 10-Ks
Health care peers:
SOLVEWSTEZBHAINCY
NYSE Health care · Lab Instruments

Agilent Technologies A

A quote by TradingView
Employees
18,100
Headquarters
Santa Clara, CA
CEO
Padraig McDonnell
Next results
around Nov 23, 2026
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $6.9B through the costs to a net profit of $1.3B · income statement of the 10-K

21% operating margin
Revenue to Gross profit: $3.6BRevenue to Cost of revenue: $3.3BGross profit to Operating profit: $1.5BGross profit to Operating expenses: $2.2BOperating profit to Net profit: $1.3BOperating profit to Tax & other: $176.0MOperating expenses to R&D: $455.0MOperating expenses to SG&A: $1.7B Revenue: $6.9B REVENUE $6.9B +7% Y/Y Gross profit: $3.6B · 52% margin GROSS PROFIT $3.6B 52% margin Cost of revenue: $3.3B · 48% of revenue COST OF REVENUE $3.3B 48% of revenue Operating profit: $1.5B · 21% margin OPERATING PROFIT $1.5B 21% margin · −1% Y/Y Operating expenses: $2.2B · 31% of revenue OPERATING EXPENSES $2.2B 31% of revenue Net profit: $1.3B · 19% margin NET PROFIT $1.3B 19% margin · +1% Y/Y Tax & other: $176.0M · 3% of revenue TAX & OTHER $176.0M 3% of revenue R&D: $455.0M · 7% of revenue R&D $455.0M 7% of revenue SG&A: $1.7B · 25% of revenue SG&A $1.7B 25% of revenue
Gross profit $3.6B 52% margin
Operating profit $1.5B 21% margin · −1% Y/Y
Net profit $1.3B 19% margin · +1% Y/Y
The full income statement, year by year

A among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 6.7%, above 46% of 59 peers (their median 7.2%) REVENUE GROWTH 6.7% · above 46% Gross margin: 53.8%, above 32% of 50 peers (their median 65.2%) GROSS MARGIN 53.8% · above 32% Operating margin: 22.2%, above 80% of 50 peers (their median 13.4%) OPERATING MARGIN 22.2% · above 80% Net margin: 19.5%, above 81% of 59 peers (their median 9.5%) NET MARGIN 19.5% · above 81% FCF margin: 17.2%, above 58% of 55 peers (their median 15.2%) FCF MARGIN 17.2% · above 58% Return on capital: 11.9%, above 71% of 41 peers (their median 9.0%) RETURN ON CAPITAL 11.9% · above 71%
A Peer median Below the median

What changed

8 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Dec 22, 2025 against Dec 20, 2024.

Risk factors
8 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Critical audit matters changed
New this year: Revenue Recognition for Certain Products and Services and other Revenue (“As described in Note 1 to the consolidated financial statements, the Company derives revenue primarily from the sale of analytical and diagnostics products and services. Revenue is recognized when control of the promised products or services is transferred to the customers and the performance obliga”). No longer listed: Acquisition of BIOVECTRA - Valuation of Certain Customer Relationships
10-K · XBRL
Accounting checks
10 other checks clear, 1 worth a look
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
0 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Critical audit matters changed
    New this year: Revenue Recognition for Certain Products and Services and other Revenue (“As described in Note 1 to the consolidated financial statements, the Company derives revenue primarily from the sale of analytical and diagnostics products and services. Revenue is recognized when control of the promised products or services is transferred to the customers and the performance obliga”). No longer listed: Acquisition of BIOVECTRA - Valuation of Certain Customer Relationships
  • Receivables +12.3% vs revenue +6.7% (+5.6 pts)
9 more checks with nothing to note
  • Cash from operations $1.6B vs net income $1.3B (FY ending Oct 31, 2025)
  • Inventory +5.5% vs revenue +6.7% (-1.3 pts)
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

8 paragraphs in Risk Factors that were not in the 10-K filed Dec 20, 2024. Quoted as filed.

All 8 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Dec 20, 2024 10-K, ITEM 1A
    Recent and dynamic government rule making and policy changes could increase our costs, affect our markets and customers and impact our results of operations. The rapid increase in new government regulations, including tariffs and proposed tariffs in the geographies and markets in which we operate, could result in significant costs and…
  2. Item 1A · new paragraph · not in the 10-K filed Dec 20, 2024 10-K, ITEM 1A
    The expectations and requirements of regulators and other key stakeholders, including on corporate governance and sustainability-related matters, continue to evolve and diverge, and our ability to meet these expectations and requirements could impact our risk exposure and financial conditions. We are subject to rapidly changing and…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$6.8B$6.8B$6.5B$6.9B
Net income$1.3B$1.2B$1.3B$1.3B
Operating cash flow$1.3B$1.8B$1.8B$1.6B
Free cash flow$1.0B$1.5B$1.4B$1.2B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$6.9B ▲ 6.7% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

No new filings in the last 30 days · SEC EDGAR

All filings

Nothing new. The most recent filings:

About the company

Agilent Technologies, Santa Clara, CA · from the 10-K filed Dec 22, 2025

Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. In November 2024, we announced a change in our organizational structure to support our market-focused, customer-centric strategy. Our former Diagnostics and Genomics segment combined with our liquid chromatography and liquid chromatography mass spectrometry instrument platforms to form our new Life Sciences and Diagnostics Markets segment.

Headquarters
Santa Clara, CA
Country
United States
Listed on
NYSE
Fiscal year ends
October 31
Last results
Aug 26, 2026
Incorporated in
DE

Employees, at the top of the page: "As of October 31, 2025, we employed approximately 18,100 people worldwide" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Dec 22, 2025 (open at SEC), compared with the 10-K filed Dec 20, 2024. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/A/export.csv") into a cell.